VALNEVA Declaration of shares and voting rights March 31, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this...
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is...
Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023...
Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €126.1 million at year-end 2023 enhanced by €95 million from sale of Priority Review Voucher (PRV) 1 Extended the interest-only period of existing debt financing agreement to January 2026 significantly extending cash runway 2 Operational...
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of its existing loan by eighteen months. Reimbursements of the first $100 million tranche will now start in January 2026 instead...
Timeframe : 1H - Simple chart
Status : TARGET REACHED
The bullish trend is currently very strong on VALNEVA. As long as the price remains above the support at 3.400 EUR, you could try to benefit from the boom. The first bullish objective is located at
Timeframe : Weekly - Simple chart
Status : INVALID
VALNEVA is part of a very strong bearish trend. Traders may consider trading only short positions (for sale) as long as the price remains well below 3.653 EUR. The next support located at 2.758 EUR is
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen...